ACTG 372:PROLONGATION OF VIROLOGIC SUCCESS & OPTIONS FOR FAILURE IN H

仅限核心实验室-样品处理。 本试验是一项具有待评价的平行问题的研究。 ACTG 372的总体原理是探索相关问题，同时检查已接受ZDV（或d4 T）+3TC+IDV且目前表现出一系列病毒学应答的入组者的新治疗选择。 通过将研究分为相应的非序贯队列，可以探索评估病毒学成功和病毒学失败的不同方法，同时保持对受试者的长期随访。 为ACTG试验中接受特定治疗方案的所有受试者提供入组选择（无论缓解情况如何）是一个理想的目标，因为可以并行并以有效的方式寻求管理缓解和失败的新方法。

CORE LAB ONLY - SAMPLE PROCESSING. This trial is a study with parallel questions to be evaluated. The overarching rational for ACTG 372 is to explore relevant questions while examining new treatment options for enrollees who have been receiving ZDV (or d4T) +3TC+IDV and are currently exhibiting a range of virologic responses. By dividing the study into the corresponding, non-sequential cohorts, different approaches to evaluating virologic success and virologic failure can be explored while maintaining long-term follow-up of subjects. Providing rollover options for all subjects on a particular regimen in an ACTG trial, irrespective of response, is a desirable goal as new approaches to managing response and failure can be pursued in parallel and in an efficient manner.